Trial
NCT03952832
Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
City of Hope Medical Center
Collaborators
National Cancer Institute (NCI)
Condition
Smoldering Plasma Cell Myeloma
Intervention
Leflunomide
Why stopped
Budget issues
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-11-14